Based on lesion size and type, treatment recommendations for CNV differ significantly. Photocoagulation was indicated for classic CNV only, photodynamic therapy (PDT) was recommended for classic CNV of any size, but only for small occult lesions and no official guideline allowed PDT of minimally classic CNV. Antiangiogenic therapy appears to allow an all-lesion-types approach. However, subgroup analysis has demonstrated a superior effect in predominantly classic CNV and smaller lesions in the VISION (VEGF Inhibition Study in Ocular Neovascularization) trial, and best results for minimally classic CNV.
5 Promising results concerning the prevention of vision loss were found in the ANCHOR (
Anti-VEGF Antibody for the Treatment of Predominantly Classic
Choroidal Neovascularization in AMD) trial (Brown DM et al.
IOVS 2006;47:E-Abstract 2963) including predominantly classic CNV, where over 94% of patients (94.3% receiving 0.3 mg ranibizumab; 96.4% receiving 0.5 mg ranibizumab) lost fewer than 15 letters (ETDRS [Early Treatment Diabetic Retinopathy Study]chart) from baseline visual acuity, versus 64.3% of patients in the PDT group. The MARINA trial (
Minimally classic/occult trial of the
Anti-VEGF antibody
Ranibizumab
In the treatment of
Neovascular
AMD) focusing on minimally classic and occult lesion types showed that nearly 95% of patients receiving ranibizumab (0.3 or 0.5 mg) lost fewer than 15 letters compared with 62% of patients receiving a sham injection (Heier JS et al.
IOVS 2006;47:E-Abstract 2959; Webster MK et al.
IOVS 2006;47:E-Abstract 2206; Chang TS et al.
IOVS 2006;47:E-Abstract 5252). The proportion of patients showing a significant improvement of more than 3 lines was highest in the ANCHOR trial, with predominantly classic lesions. Current pathway-based therapy results depend much less on lesion morphology, as defined using conventional fluorescein angiography (FA). Because anti-VEGF therapy is basically an antileakage strategy, the exudative morphology of a lesion becomes more relevant. Clearly, the nature of the neovascular process and, with antiangiogenic therapy, the leakage characteristics of a CNV lesion have to be understood. To evaluate the efficacy of any treatment modality, to develop adequate treatment strategies and retreatment regimens, an accurate diagnosis and identification of exudative patterns is fundamental. The main diagnostic tool is FA, where information is often limited by masking phenomena. Because of the short wavelength, fluorescence is nearly completely absorbed by the RPE, blood, or fluid, and underlying processes remain obscure.
6 7 8 9 Information about activity and extent of subretinal structures is more easily accessible by indocyanine green angiography (ICGA). The dye is more effective in the near infrared spectrum, enables better transmission through pigment and exudation,
10 and should therefore improve imaging of occult lesions, leakage, and its origin.
11 12 With the introduction of the confocal scanning laser ophthalmoscope (SLO),
13 the diagnostic efficacy has been improved by combining optimal contrast, high sensitivity, and resolution up to 300 μm.
14 15 The confocal modality allows sequential tomographic imaging with 32 angiographic sections over a 4- to 6-mm thickness.
7 Localization of fluorescence to the individual tomographic section offers a depth profile of fluorescence compared with a flat conventional intensity profile. Three-dimensional (3D) reconstruction of the fluorescence distribution results in a 3D relief of vascular structures and dynamic changes such as perfusion and leakage. Hence, topographic angiography offers a realistic imaging of the lesion architecture, perfusion, and extravasation. The purpose of our study was to apply this recent technique of topographic image processing to two main CNV types, classic and occult, and to identify characteristic features. The diagnostic potential of the new method was further evaluated by comparison with conventional 2D angiography.